Ye X, et al. - In this cohort study, researchers assessed aldo-keto reductase family 1 member B10 (AKR1B10), a secretory protein overexpressed in hepatocellular carcinoma (HCC), as a new serum marker for detection of HCC. For this investigation, 1,244 participants were consecutively enrolled from 3 independent hospitals, including HCC, healthy controls (HCs), benign liver tumors (BLTs), chronic hepatitis B (CHB), and liver cirrhosis (LC). According to findings, AKR1B10 is a new potent serum marker for HCC and early-stage HCC detection with better diagnostic performance than alpha-fetoprotein (AFP). Combining AKR1B10 with AFP enhanced HCC diagnostic accuracy compared with AKR1B10 or AFP alone.